About Ovid therapeutics
Ovid Therapeutics is a biopharmaceutical company that is dedicated to transforming the lives of people affected by rare neurological diseases. The company's mission is to develop innovative therapies that can address the unmet medical needs of patients suffering from Angelman syndrome, Fragile X syndrome, and rare epilepsies.
At Ovid Therapeutics, the team believes in taking bold steps towards finding solutions for these debilitating conditions. They are committed to developing treatments that can improve the quality of life for patients and their families. With a focus on precision medicine, Ovid Therapeutics aims to provide personalized therapies that can target specific genetic mutations associated with these disorders.
One of the key areas of research at Ovid Therapeutics is Angelman syndrome (AS). This rare genetic disorder affects approximately 1 in 15,000 individuals worldwide and is characterized by developmental delays, intellectual disability, seizures, and speech impairments. There are currently no approved treatments for AS, but Ovid Therapeutics is working on developing a therapy called OV101 that targets GABA receptors in the brain. This drug has shown promising results in clinical trials and could potentially improve sleep patterns and reduce hyperactivity in AS patients.
Fragile X syndrome (FXS) is another rare genetic disorder that affects approximately 1 in 4,000 males and 1 in 8,000 females worldwide. It causes intellectual disability as well as behavioral problems such as anxiety and hyperactivity. Ovid Therapeutics has developed a drug called OV935 which targets both GABA receptors and enzymes involved in regulating glutamate levels in the brain. This drug has shown potential for reducing seizures as well as improving behavior symptoms associated with FXS.
In addition to AS and FXS, Ovid Therapeutics also focuses on developing treatments for other rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. These conditions are characterized by frequent seizures which can be difficult to control with existing medications.
Ovid Therapeutics' approach involves collaborating with leading researchers around the world to identify new therapeutic targets based on genetics or other biological factors underlying these disorders. By leveraging cutting-edge technologies such as CRISPR gene editing or RNA interference (RNAi), they aim to develop highly targeted therapies that can address specific disease mechanisms.
Overall, Ovid Therapeutics represents an exciting new frontier in biopharmaceutical research focused on addressing unmet medical needs for patients suffering from rare neurological diseases like Angelman Syndrome or Fragile X Syndrome through innovative precision medicine approaches aimed at transforming lives one patient at a time!